It was concluded that anti-inflammatory therapy targeting the IL-1β innate immunity pathway with canakinumab led to a significantly lower rate of recurrent cardiovascular events independent of lipid-level lowering, therefore bringing out the importance of inflammation in atherosclerosis [70]. Here, IL1B is linked to atherosclerosis.